




FY2010 3rd Quarter Business Results

(FY2010, ending March 31, 2010)

February 2, 2010
IR & Corporate Communication Div.

3rd Quarter Financial Results



* Capital expenditure; ¥2.5billion
Depreciation and amortization; ¥5.1billion
R&D expenditure; ¥8.1billion

	First 9 Months of FY2010		First 9 Months of FY2009		% over a Year Earlier
		Ratio		Ratio	
Net Sales	83.1	100%	80.6	100%	103.1%
Operating Income	11.1	13.4%	10.0	12.5%	110.3%
Ordinary Income	11.0	13.3%	7.8	9.8%	140.5%
Net Income	6.7	8.1%	4.6	5.7%	146.2%

● Despite the effects of yen appreciation, net sales and income reached record highs, as operations expanded in China and other overseas regions.

- Overseas, sales and income increased in all geographic regions on a local currency basis.
- In Japan, sales and income fell, largely owing to the effects of yen appreciation.
- Profitability improved, due partly to expanded reagent sales.
- Yen appreciation reduced net sales ¥7.0 billion and operating income ¥4.1 billion.

Note: At the exchange rates prevailing one year earlier, net sales would have been up 11.9% year on year, and operating income up 51.3%.


● Exchange Rate (In JPY)	First 9 Months of FY2010		First 9 Months of FY2009	
	1US\$	1EUR	1US\$	1EUR
1US\$	93.6	133.0	102.8	150.7
1EUR				

Breakdown of Net Sales and Operating Income



Net Sales

* FX impact excluded from each regional sales below




Operating Income

(In billions of JPY)

Gross margin increased as a result of an improvement in cost ratio

Gross margin on increased sales



SG&A increase

- Depreciation of Technopark ¥0.1 billion
- Direct sales and support in Benelux ¥1 billion

FX impact

Topics

- Enhanced lineup of reagents for HISCL-2000i in the immunochemistry segment
 - ▶ Launched five reagent items, including those for cancer tumors (total of 20 items)
- Launched a research reagent for detecting avian-derived influenza virus nucleoproteins (November)
 - ▶ Shortens the detection process to about 10 minutes
- Opened a reagent development base in China (December)
- Converted to a wholly owned subsidiary a company in Germany specializing in sales and support of POCT products (January)
 - ▶ Established a structure employing telemarketing and other sales methods
- Established a subsidiary in Spain to expand our life science business (January)
 - ▶ Promoting sales of a detector for breast cancer metastases in the sentinel lymph node
- Held scientific seminars in China, Taiwan, Vietnam and other countries
 - ▶ In China, held the 12th Sysmex Scientific Seminar (the largest scientific seminar held by a single company)



12th Sysmex Scientific Seminar
(Kunming, Yunnan Province)

Net Sales by Geographical Region



		First 9 Months of FY2010		First 9 Months of FY2009		(In billions of JPY) Growth	
			Ratio		Ratio	(JPY)	(Local currency)
Net Sales		83.1	100%	80.6	100%	103.1%	
Region	Americas	16.5	20.0%	17.3	21.6%	95.4%	104.9%
	Europe	26.9	32.4%	26.7	33.2%	100.6%	114.0%
	China	8.7	10.5%	6.8	8.5%	127.7%	139.1%
	AP	4.2	5.1%	4.0	5.1%	104.7%	117.0%
	Japan*	26.6	32.0%	25.5	31.6%	104.2%	104.2%

* Including Korea, Taiwan, and Mongolia, etc.



	First 9 Months of FY2010	First 9 Months of FY2009	(In JPY)
1US\$	93.6	102.8	
1EUR	133.0	150.7	
1RMB	13.7	14.9	
1SG\$	65.2	72.8	

Geographic Segment Information: Americas



	First 9 Months of FY2010	First 9 Months of FY2009	% over a Year Earlier
Net Sales	16.5	17.3	95.4%
Operating Income	1.8	1.1	166.4%

* On a local currency basis: Net sales, 104.9%; Operating income, 182.9%



Geographic Segment Information: Europe





	First 9 Months of FY2010	First 9 Months of FY2009	% over a Year Earlier
Net Sales	26.9	26.7	100.6%
Operating Income	3.8	3.7	102.8%

* On a local currency basis: Net sales, 114.0%; Operating income, 116.5%

- **Sales rose, owing to steady conversion to direct sales.**

- ▶ Benelux, which commenced direct sales in April, contributed to sales.
- ▶ The start of direct sales in France and continued success in securing projects in the United Kingdom boosted sales in the hematology field.
- ▶ Sales rose in the hemostasis field.
- ▶ Distributor sales were lackluster in Italy, Spain and other areas.

- **Conversion to direct sales and reagent sales growth pushed up operating income.**



* Reform accounting standards for lease

Geographic Segment Information: China




	First 9 Months of FY2010	First 9 Months of FY2009	% over a Year Earlier
Net Sales	8.7	6.8	127.7%
Operating Income	2.1	0.83	259.0%

* On a local currency basis: Net sales, 139.1%; Operating income, 281.4%

- In line with growing demand for medical care, sales in the hematology and non-hematology fields rose substantially.

- ▶ Hematology, hemostasis and urinalysis sustained double-digit growth.
- ▶ Promotion of direct business with customers and measures to reinforce the distributor structure bolstered sales of high-end hematology analyzers.

- Operating income grew significantly, owing to a major sales increase and reduction of the fixed cost ratio through expanded use of distributors.



Geographic Segment Information: AP





	First 9 Months of FY2010	First 9 Months of FY2009	% over a Year Earlier
Net Sales	4.2	4.0	104.7%
Operating Income	0.74	0.51	146.2%

* On a local currency basis: Net sales, 117.0%; Operating income, 163.0%

- **Sales rose through the expansion of business in the hematology field, particularly in Southeast Asia.**
 - ▶ Sales of hematology systems increased in Indonesia, the Philippines and other countries.
 - ▶ Sales of compact, high-end analyzers (XS series) were robust in Thailand and India.

- **Operating income surged, thanks to higher sales and reduced SG&A expenses.**



Geographic Segment Information: Japan




	First 9 Months of FY2010	First 9 Months of FY2009	(In billions of JPY) % over a Year Earlier
Net Sales	48.0	50.2	95.8%
Sales to Customers	Japan	25.3	24.2
	Korea, Taiwan, and Mongolia, etc.	1.2	1.3
Intra-area Transfer	21.4	24.6	87.0%
Operating Income	2.2	4.0	55.1%

● Japanese market

- ▶ Instrument sales fell in a severe market.
- ▶ Solid acquisition of new projects in the hematology field.
- ▶ Sales of urinalysis systems grew.
- ▶ Sales of simplified test kits increased substantially because of the spread of pandemic flu.


● Inter-area transfers to overseas affiliates decreased due to yen appreciation.

● Operating income decreased, due partly to yen appreciation.



FY2010 Consolidated Earnings Forecast

- Net Sales: ¥117 billion
- Operating Income: ¥15 billion
- Net Income: ¥9.2 billion
- Operating Margin: 12.8 %
- Net Income Margin: 7.9 %



(For the years ended March 31)



We Believe the Possibilities.

Sysmex Corporation

<Contact>

IR & Corporate Communication Div.

Phone: +81-78-265-0500

Email: info@sysmex.co.jp

URL www.sysmex.co.jp